Bryn Mawr Capital Management LLC Has $5.02 Million Stake in Pfizer Inc. (NYSE:PFE)

Bryn Mawr Capital Management LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 28.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 174,416 shares of the biopharmaceutical company’s stock after selling 69,173 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Pfizer were worth $5,021,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Stanley Laman Group Ltd. grew its position in shares of Pfizer by 411.2% in the fourth quarter. Stanley Laman Group Ltd. now owns 55,599 shares of the biopharmaceutical company’s stock valued at $1,601,000 after purchasing an additional 44,722 shares during the last quarter. Jackson Hole Capital Partners LLC grew its position in Pfizer by 3.8% during the fourth quarter. Jackson Hole Capital Partners LLC now owns 90,415 shares of the biopharmaceutical company’s stock worth $2,603,000 after buying an additional 3,342 shares in the last quarter. Van Cleef Asset Management Inc grew its position in Pfizer by 6.8% during the fourth quarter. Van Cleef Asset Management Inc now owns 88,258 shares of the biopharmaceutical company’s stock worth $2,541,000 after buying an additional 5,613 shares in the last quarter. Syon Capital LLC grew its position in Pfizer by 111.4% during the fourth quarter. Syon Capital LLC now owns 64,444 shares of the biopharmaceutical company’s stock worth $1,855,000 after buying an additional 33,961 shares in the last quarter. Finally, Disciplined Equity Management Inc. grew its position in Pfizer by 1,047.6% during the fourth quarter. Disciplined Equity Management Inc. now owns 2,410 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 2,200 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Stock Up 0.5 %

Shares of PFE opened at $25.38 on Friday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The stock has a market capitalization of $143.72 billion, a price-to-earnings ratio of 70.50, a PEG ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a fifty day moving average of $26.96 and a 200-day moving average of $28.42.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the prior year, the company earned $1.14 EPS. Pfizer’s revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.62%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.